CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6 inhibitor abemaciclib for treatment of EAC. In vitro, apoptosis, proliferation, and pathway regulation were evaluated in OE19, OE33, and FLO1 E...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosovec, Juliann E., Zaidi, Ali H., Omstead, Ashten N., Matsui, Daisuke, Biedka, Mark J., Cox, Erin J., Campbell, Patrick T., Biederman, Robert W.W., Kelly, Ronan J., Jobe, Blair A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725031/
https://www.ncbi.nlm.nih.gov/pubmed/29245989
http://dx.doi.org/10.18632/oncotarget.22244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725031/
https://www.ncbi.nlm.nih.gov/pubmed/29245989
http://dx.doi.org/10.18632/oncotarget.22244

Ejemplares similares